x
Filter:
Filters applied
- Multimedia Library
- American Journal of CardiologyRemove American Journal of Cardiology filter
Author
- Kimura, Takeshi13
- Morimoto, Takeshi11
- Furukawa, Yutaka8
- Shiomi, Hiroki8
- Chothani, Ankit7
- Nakagawa, Yoshihisa7
- Singh, Vikas7
- Badheka, Apurva O6
- Deshmukh, Abhishek6
- Patel, Nileshkumar J6
- Arora, Shilpkumar5
- Ballantyne, Christie M5
- Mehran, Roxana5
- Sakata, Ryuzo5
- Serruys, Patrick W5
- Soliman, Elsayed Z5
- Stone, Gregg W5
- Alonso, Alvaro4
- Généreux, Philippe4
- Hanyu, Michiya4
- Ellinor, Patrick T3
- Filion, Kristian B3
- Fukuda, Keiichi3
- Toyota, Toshiaki3
- Abbate, Antonio2
Multimedia Library
278 Results
- Congenital Heart Disease
Impact of Hospital Volume on Outcomes of Endovascular Stenting for Adult Aortic Coarctation
American Journal of CardiologyVol. 116Issue 9p1418–1424Published online: September 2, 2015- Parth Bhatt
- Nileshkumar J. Patel
- Achint Patel
- Rajesh Sonani
- Aashay Patel
- Sidakpal S. Panaich
- and others
Cited in Scopus: 8Use of transcatheter endovascular stenting has been increasing in the treatment of coarctation of aorta (CoA). The present study was undertaken on adults with CoA who underwent stent placement from 2000 to 2011 to analyze the relation of hospital volumes to the outcomes of stenting in adults with CoA. It was a retrospective study based on Healthcare Cost and Utilization Project's Nationwide Inpatient Sample (NIS) database from 2000 to 2011 and identified subjects using the International Classification of Diseases, Ninth Revision, Clinical Modification procedure code of 747.10 (CoA). - Coronary Artery Disease
Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions
American Journal of CardiologyVol. 116Issue 9p1321–1328Published online: August 13, 2015- Robert L. Page II
- Vahram Ghushchyan
- Richard A. Read
- Cynthia L. Hartsfield
- Bruce R. Koch II
- Kavita V. Nair
Cited in Scopus: 9Comparative studies evaluating traditional versus newer antianginal (AA) medications in chronic stable angina pectoris (CSA) on cardiovascular (CV) outcomes and utilization are limited, particularly in patients with diabetes mellitus (DM). Claims data (2008 to 2012) were analyzed using a commercial database. Patients with CSA receiving a β blocker (BB), calcium channel blocker (CCB), long-acting nitrate (LAN), or ranolazine were identified and followed for 12 months after a change in AA therapy. - Coronary Artery Disease
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel
American Journal of CardiologyVol. 116Issue 3p384–392Published online: May 11, 2015- Hai-Bin Chen
- Xin-Lu Zhang
- Hong-Bin Liang
- Xue-Wei Liu
- Xin-Yu Zhang
- Bao-Yi Huang
- and others
Cited in Scopus: 8The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding. However, it remains unclear if the risks of bleeding outweigh those of MACEs in patients on prasugrel treatment. We systematically reviewed randomized controlled trials comparing prasugrel with clopidogrel in patients with CAD. We performed a literature search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trial databases from inception to November 25, 2014, and reviewed the reference lists of retrieved articles. - Coronary Artery Disease
Event Rates in Randomized Clinical Trials Evaluating Cardiovascular Interventions and Devices
American Journal of CardiologyVol. 116Issue 3p355–363Published online: May 8, 2015- Karim D. Mahmoud
- Ryan J. Lennon
- David R. Holmes Jr.
Cited in Scopus: 3Randomized clinical trials (RCTs) are considered the gold standard for evidence-based medicine. However, an accurate estimation of the event rate is crucial for their ability to test clinical hypotheses. Overestimation of event rates reduces the required sample size but can compromise the statistical power of the RCT. Little is known about the prevalence, extent, and impact of overestimation of event rates. The latest RCTs on 10 preselected topics in the field of cardiovascular interventions and devices were selected, and actual primary event rates in the control group were compared with their respective event rate estimations. - Coronary Artery Disease
Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention
American Journal of CardiologyVol. 116Issue 2p174–186Published online: April 23, 2015- Philippe Généreux
- Carlos M. Campos
- Vasim Farooq
- Christos V. Bourantas
- Friedrich W. Mohr
- Antonio Colombo
- and others
Cited in Scopus: 31Incomplete revascularization is common after percutaneous coronary intervention (PCI). Whether a “reasonable” degree of incomplete revascularization is associated with a similar favorable long-term prognosis compared with complete revascularization remains unknown. We sought to quantify the proportion of coronary artery disease burden treated by PCI and evaluate its impact on outcomes using a new prognostic instrument—the Synergy Between PCI with Taxus and Cardiac Surgery (SYNTAX) Revascularization Index (SRI). - Coronary Artery Disease
Long-Term Outcomes After Coronary Stent Implantation in Patients Presenting With Versus Without Acute Myocardial Infarction (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2)
American Journal of CardiologyVol. 116Issue 1p15–23Published online: April 22, 2015- Kyohei Yamaji
- Masahiro Natsuaki
- Takeshi Morimoto
- Koh Ono
- Yutaka Furukawa
- Yoshihisa Nakagawa
- and others
Cited in Scopus: 9It has not been adequately addressed yet how long the excess cardiovascular event risk persists after acute myocardial infarction (AMI) compared with stable coronary artery disease. Of 10,470 consecutive patients who underwent percutaneous coronary intervention either with sirolimus-eluting stent (SES) only or with bare-metal stent (BMS) only in the Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2, 3,710 (SES: n = 820 and BMS: n = 2,890) and 6,760 patients (SES: n = 4,258 and BMS: n = 2,502) presented with AMI (AMI group) and without AMI (non-AMI group), respectively. - Valvular Heart Disease
Prevalence and Prediction of Obstructive Coronary Artery Disease in Patients Referred for Valvular Heart Surgery
American Journal of CardiologyVol. 116Issue 2p280–285Published online: April 18, 2015- Jason M. Lappé
- Justin L. Grodin
- Yuping Wu
- Corinne Bott-Silverman
- Leslie Cho
Cited in Scopus: 7Current guidelines recommend a coronary evaluation before valvular heart surgery (VHS). Diagnostic coronary angiography is recommended in patients with known coronary artery disease (CAD) and those with high pretest probability of CAD. In patients with low or intermediate pretest probability of CAD, the guidelines recommend coronary computed tomographic angiography. However, there are no tools available to objectively assess a patient’s risk for obstructive CAD before VHS. To address this deficit, 5,360 patients without histories of CAD who underwent diagnostic coronary angiography as part of preoperative evaluation for VHS were identified. - Review
Review of Eligibility for Cardiac Resynchronization Therapy
American Journal of CardiologyVol. 116Issue 2p318–324Published online: April 18, 2015- Nathaniel M. Hawkins
- Matthew T. Bennett
- Jason G. Andrade
- Sean A. Virani
- Andrew D. Krahn
- Andrew Ignaszewski
- and others
Cited in Scopus: 2Cardiac resynchronization therapy (CRT) is underused. Recent guidelines have expanded indications for CRT to include less severe symptoms but now favor left bundle branch block morphology in patients with moderate QRS prolongation. The prevalence of CRT eligibility according to historical and current guidelines is uncertain. The aim of this review was to identify and synthesize all existing published research reporting the prevalence of CRT eligibility. A systematic review of electronic databases including MEDLINE, Embase, and the Cochrane Library was performed. - Coronary Artery Disease
Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)
American Journal of CardiologyVol. 116Issue 2p167–173Published online: April 16, 2015- Steven M. Bradley
- Paul S. Chan
- Pamela M. Hartigan
- Brahmajee K. Nallamothu
- William S. Weintraub
- Steven P. Sedlis
- and others
Cited in Scopus: 17Establishing the validity of appropriate use criteria (AUC) for percutaneous coronary intervention (PCI) in the setting of stable ischemic heart disease can support their adoption for quality improvement. We conducted a post hoc analysis of 2,287 Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial patients with stable ischemic heart disease randomized to PCI with optimal medical therapy (OMT) or OMT alone. Within appropriateness categories, we compared rates of death, myocardial infarction, revascularization subsequent to initial therapy, and angina-specific health status as determined by the Seattle Angina Questionnaire in patients randomized to PCI + OMT to those randomized to OMT alone. - Coronary Artery Disease
Meta-Analysis of Long-Term Clinical Outcomes of Everolimus-Eluting Stents
American Journal of CardiologyVol. 116Issue 2p187–194Published online: April 16, 2015- Toshiaki Toyota
- Hiroki Shiomi
- Takeshi Morimoto
- Takeshi Kimura
Cited in Scopus: 24The superiority of everolimus-eluting stents (EES) over sirolimus-eluting stents (SES) for long-term clinical outcomes has not been yet firmly established. We conducted a systematic review and a meta-analysis of randomized controlled trials (RCTs) comparing EES directly with SES using the longest available follow-up data. We searched PubMed, the Cochrane database, and ClinicalTrials.gov for RCTs comparing outcomes between EES and SES and identified 13,434 randomly assigned patients from 14 RCTs. - Arrhythmias and Conduction Disturbances
Effect of Race on Outcomes (Stroke and Death) in Patients >65 Years With Atrial Fibrillation
American Journal of CardiologyVol. 116Issue 2p230–235Published online: April 16, 2015- Rajesh Kabra
- Peter Cram
- Saket Girotra
- Mary Vaughan Sarrazin
Cited in Scopus: 31Atrial fibrillation (AF) is associated with stroke and death. We sought to determine whether there are any racial differences in the outcomes of death and stroke in patients with AF. We used Medicare administrative data from January 1, 2010, to December 31, 2011, to identify 517,941 patients with newly diagnosed AF. Of these, 452,986 patients (87%) were non-Hispanic white, 36,425 (7%) were black, and 28,530 (6%) were Hispanic. The association between race and outcomes of death and stroke were measured using Cox proportional hazard models. - Valvular Heart Disease
Trends of Hospitalizations in the United States from 2000 to 2012 of Patients >60 Years With Aortic Valve Disease
American Journal of CardiologyVol. 116Issue 1p132–141Published online: April 15, 2015- Apurva O. Badheka
- Vikas Singh
- Nileshkumar J. Patel
- Shilpkumar Arora
- Nilay Patel
- Badal Thakkar
- and others
Cited in Scopus: 26In recent years, there has been an increased emphasis on the diagnosis and treatment of valvular heart disease and, in particular, aortic stenosis. This has been driven in part by the development of innovative therapeutic options and by an aging patient population. We hypothesized an increase in the number of hospitalizations and the economic burden associated with aortic valve disease (AVD). Using Nationwide Inpatient Sample from 2000 to 2012, AVD-related hospitalizations were identified using International Classification of Diseases, Ninth Revision, Clinical Modification, code 424.1, as the principal discharge diagnosis. - Review
Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure
American Journal of CardiologyVol. 116Issue 1p155–161Published online: April 9, 2015- Connor A. Emdin
- Tom Callender
- Jun Cao
- John J.V. McMurray
- Kazem Rahimi
Cited in Scopus: 29Renin-angiotensin-aldosterone system (RAAS) inhibition is 1 of the most effective strategies for the management of heart failure with reduced systolic function. However, trials that included patients with preserved systolic function have not shown a clear beneficial effect. Pooling evidence from several heart failure trials provides the opportunity to better assess the differential effects of RAAS inhibition across the continuum of systolic function. The authors searched MEDLINE for large-scale trials published from 1966 to March 2014 that compared RAAS inhibitors against placebos. - Coronary Artery Disease
Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry)
American Journal of CardiologyVol. 116Issue 1p37–42Published online: April 7, 2015- Marco G. Mennuni
- Jonathan L. Halperin
- Sameer Bansilal
- Mikkel M. Schoos
- Kleanthis N. Theodoropoulos
- Omar A. Meelu
- and others
Cited in Scopus: 30Patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) are at elevated risk for bleeding and thromboembolic ischemic events. Currently, guidelines on antithrombotic treatment for these patients are based on weak consensus. We describe patterns and determinants of antithrombotic prescriptions in this population. The Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI Registry was an international observational study of 859 consecutive patients with AF who underwent PCI from 2009 to 2011. - Arrhythmias and Conduction Disturbances
Comparative Effectiveness of Cardiac Resynchronization Therapy Defibrillators Versus Standard Implantable Defibrillators in Medicare Patients
American Journal of CardiologyVol. 116Issue 1p79–84Published online: April 7, 2015- Robbert Zusterzeel
- Daniel A. Caños
- William E. Sanders
- Henry Silverman
- Thomas E. MaCurdy
- Christopher M. Worrall
- and others
Cited in Scopus: 1Previous analyses have shown that there is lower mortality with cardiac resynchronization therapy defibrillators (CRT-D) in patients with left bundle branch block (LBBB) but demonstrated mixed results in patients without LBBB. We evaluated the comparative effectiveness of CRT-D versus standard implantable defibrillators (ICDs) separately in patients with LBBB and right bundle branch block (RBBB) using Medicare claims data. Medicare records from CRT-D and ICD recipients from 2002 to 2009 that were followed up for up to 48 months were analyzed. - Coronary Artery Disease
Management and Long-Term Prognosis of Spontaneous Coronary Artery Dissection
American Journal of CardiologyVol. 116Issue 1p66–73Published online: April 7, 2015- Corrado Lettieri
- Dennis Zavalloni
- Roberta Rossini
- Nuccia Morici
- Federica Ettori
- Ornella Leonzi
- and others
Cited in Scopus: 167The optimal management and short- and long-term prognoses of spontaneous coronary artery dissection (SCAD) remain not well defined. The aim of this observational multicenter study was to assess long-term clinical outcomes in patients with SCAD. In-hospital and long-term outcomes were assessed in 134 patients with documented SCAD, as well as the clinical impact and predictors of a conservative rather than a revascularization strategy of treatment. The mean age was 52 ± 11, years and 81% of patients were female. - Valvular Heart Disease
Reliability, Agreement, and Presentation of a Reference Standard for Assessing Implanted Heart Valve Sizes by Multidetector-Row Computed Tomography
American Journal of CardiologyVol. 116Issue 1p112–120Published online: April 7, 2015- Dominika Suchá
- Ceranza G. Daans
- Petr Symersky
- R. Nils Planken
- Willem P.Th.M. Mali
- Lex A. van Herwerden
- and others
Cited in Scopus: 10The implanted prosthetic heart valve (PHV) size is vital for the evaluation of suspected PHV dysfunction and in case of reoperation or valve-in-valve transcatheter approaches. The labeled size is not always known, and discrepancies exist between manufacturers' labeled sizes and true sizes. Reproducible methods for noninvasive PHV size assessment are lacking. We determined the reliability and agreement of PHV size measurements using multidetector-row computed tomography (MDCT) and provide reference values of MDCT measurements compared with manufacturer specifications. - Valvular Heart Disease
Impact on Left Ventricular Function and Remodeling and on 1-Year Outcome in Patients With Left Bundle Branch Block After Transcatheter Aortic Valve Implantation
American Journal of CardiologyVol. 116Issue 1p125–131Published online: April 7, 2015- Nazario Carrabba
- Renato Valenti
- Angela Migliorini
- Marco Marrani
- Giulia Cantini
- Guido Parodi
- and others
Cited in Scopus: 55Conflicting results have been reported about the prognostic impact of left bundle branch block (LBBB) after transcatheter aortic valve implantation (TAVI). The aim of this study was to evaluate the impact of LBBB after TAVI on left ventricular (LV) function and remodeling and on 1-year outcomes. Of 101 TAVI patients, 9 were excluded. All complications were evaluated according to the Valve Academic Research Consortium 2 definition. Of 92 patients, 34 developed LBBB without more advanced myocardial damage or inflammation biomarkers in comparison with patients without LBBB. - Coronary Artery Disease
Meta-Analysis of the Impact on Mortality of Noninfarct-Related Artery Coronary Chronic Total Occlusion in Patients Presenting With ST-Segment Elevation Myocardial Infarction
American Journal of CardiologyVol. 116Issue 1p8–14Published online: April 6, 2015- Stephen A. O'Connor
- Philippe Garot
- Francesca Sanguineti
- Loes P. Hoebers
- Thierry Unterseeh
- Hakim Benamer
- and others
Cited in Scopus: 29Several observational studies have compared clinical outcome in patients with a co-existing noninfarct-related artery chronic total occlusion (n-IRA CTO) versus those without, suggesting increased all-cause mortality. The goal of this study was to provide a systematic review and meta-analysis evaluating the impact of the presence of an n-IRA CTO on short- and long-term mortality after primary percutaneous coronary intervention. Studies published from January 1980 to January 2014 that compared the incidence of all-cause mortality in patients with ST-segment elevation myocardial infarction with co-existing n-IRA CTO versus those without were identified using an electronic search and reviewed using meta-analytical techniques. - Coronary Artery Disease
Comparison of Five-Year Outcome of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Triple-Vessel Coronary Artery Disease (from the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2)
American Journal of CardiologyVol. 116Issue 1p59–65Published online: April 6, 2015- Hiroki Shiomi
- Takeshi Morimoto
- Yutaka Furukawa
- Yoshihisa Nakagawa
- Junichi Tazaki
- Ryuzo Sakata
- and others
Cited in Scopus: 21Studies evaluating long-term (≥5 years) outcomes of percutaneous coronary intervention (PCI) using drug-eluting stents compared with coronary artery bypass grafting (CABG) in patients with triple-vessel coronary artery disease (TVD) are still limited. We identified 2,978 patients with TVD (PCI: n = 1,824, CABG: n = 1,154) of 15,939 patients with first coronary revascularization enrolled in the Coronary Revascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2. The primary outcome measure in the present analysis was a composite of death, myocardial infarction (MI), and stroke. - Coronary Artery Disease
Development and Validation of a Pre-Percutaneous Coronary Intervention Risk Model of Contrast-Induced Acute Kidney Injury With an Integer Scoring System
American Journal of CardiologyVol. 115Issue 12p1636–1642Published online: March 24, 2015- Taku Inohara
- Shun Kohsaka
- Takayuki Abe
- Hiroaki Miyata
- Yohei Numasawa
- Ikuko Ueda
- and others
Cited in Scopus: 33Previous models for contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention (PCI) include procedure-related variables in addition to pre-procedural variables. We sought to develop a risk model for CI-AKI based on pre-procedural variables and compare its predictability with a conventional risk model and also to develop an integer score system based on selected variables. A total of 5,936 consecutive PCIs registered in the Japanese Cardiovascular Database were analyzed (derivation cohort, n = 3,957; validation cohort, n = 1,979). - Coronary Artery Disease
Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials)
American Journal of CardiologyVol. 115Issue 12p1678–1684Published online: March 24, 2015- Eric A. Secemsky
- Alexis Matteau
- Robert W. Yeh
- Philippe Gabriel Steg
- Edoardo Camenzind
- William Wijns
- and others
Cited in Scopus: 33Studies have indicated varying mortality risks with timing of stent thrombosis (ST), but few have been adequately powered with prospective late follow-up. PROTECT randomized 8,709 subjects to either Endeavor zotarolimus-eluting or Cypher sirolimus-eluting stents. PROTECT Continued Access enrolled 1,018 patients treated with Endeavor zotarolimus-eluting stents. Subjects completed at least 4 and 3 years of follow-up, respectively. ARC-defined definite and probable ST events were stratified by time from index procedure: early (≤30 days), late (>30 and ≤360 days), and very late (>360 days). - Heart Failure
Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure
American Journal of CardiologyVol. 115Issue 10p1428–1434Published online: February 19, 2015- Abhishek Sharma
- Carl J. Lavie
- Jeffrey S. Borer
- Ajay Vallakati
- Sunny Goel
- Francisco Lopez-Jimenez
- and others
Cited in Scopus: 261Clinical studies have indicated the existence of an “obesity paradox” in patients with chronic heart failure (HF), that is, reduced mortality in patients who have elevated body mass index (BMI) scores compared with normal-weight reference groups. The aim of this study was to investigate the relation of BMI with all-cause and cardiovascular (CV) mortality and hospitalization in patients with chronic HF though a systematic review and meta-analysis of published research. PubMed, the Cumulative Index to Nursing and Allied Health Literature, Cochrane Central, Scopus, web of science and Embase were searched for studies reporting rates of total mortality, cardiac mortality, and risk for hospitalization in patients with HF in various BMI categories (<20 kg/m2 [low], 20 to 24.9 kg/m2 [normal reference], 25 to 29.9 kg/m2 [overweight], 30 to 34.9 [obese], and ≥35 kg/m2 [severely obese]). - Arrhythmias and Conduction Disturbances
Outcomes After Nonemergent Electrical Cardioversion for Atrial Arrhythmias
American Journal of CardiologyVol. 115Issue 10p1407–1414Published online: February 19, 2015- Benjamin Adam Steinberg
- Phillip Joel Schulte
- Paul Hofmann
- Mads Ersbøll
- John Hunter Alexander
- Kathleen Broderick-Forsgren
- and others
Cited in Scopus: 6Electrical cardioversion (ECV) is recommended for rhythm control in patients with atrial arrhythmia; yet, ECV use and outcomes in contemporary practice are unknown. We reviewed all nonemergent ECVs for atrial arrhythmias at a tertiary care center (2010 to 2013), stratifying patients by transesophageal echocardiography (TEE) use before ECV and comparing demographics, history, vitals, and laboratory studies. Outcomes included postprocedural success and complications and repeat cardioversion, rehospitalization, and death within 30 days. - Coronary Artery Disease
Comparison of Inhospital Mortality, Length of Hospitalization, Costs, and Vascular Complications of Percutaneous Coronary Interventions Guided by Ultrasound Versus Angiography
American Journal of CardiologyVol. 115Issue 10p1357–1366Published online: February 19, 2015- Vikas Singh
- Apurva O. Badheka
- Shilpkumar Arora
- Sidakpal S. Panaich
- Nileshkumar J. Patel
- Nilay Patel
- and others
Cited in Scopus: 32Despite the valuable role of intravascular ultrasound (IVUS) guidance in percutaneous coronary interventions (PCIs), its impact on clinical outcomes remains debatable. The aim of the present study was to compare the outcomes of PCIs guided by IVUS versus angiography in the contemporary era on inhospital outcomes in an unrestricted large, nationwide patient population. Data were obtained from the Nationwide Inpatient Sample from 2008 to 2011. Hierarchical mixed-effects logistic regression models were used for categorical dependent variables like inhospital mortality, and hierarchical mixed-effects linear regression models were used for continuous dependent variables like length of hospital stay and cost of hospitalization. - Coronary Artery Disease
Meta-Analysis of Clinical Outcomes of Patients Who Underwent Percutaneous Coronary Interventions for Chronic Total Occlusions
American Journal of CardiologyVol. 115Issue 10p1367–1375Published online: February 19, 2015- Georgios E. Christakopoulos
- Georgios Christopoulos
- Mauro Carlino
- Omar M. Jeroudi
- Michele Roesle
- Bavana V. Rangan
- and others
Cited in Scopus: 182Successful percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been associated with clinical benefit. There are no randomized controlled trials on long-term clinical outcomes after CTO PCI, limiting the available evidence to observational cohort studies. We sought to perform a weighted meta-analysis of the long-term outcomes of successful versus failed CTO PCI. A total of 25 studies, published from 1990 to 2014, with 28,486 patients (29,315 CTO PCI procedures) were included. - Arrhythmias and Conduction Disturbances
Programming Implantable Cardioverter-Defibrillator Therapy Zones to High Ranges to Prevent Delivery of Inappropriate Device Therapies in Patients With Primary Prevention: Results from the RISSY-ICD (Reduction of Inappropriate ShockS bY InCreaseD zones) trial
American Journal of CardiologyVol. 115Issue 9p1235–1243Published online: February 12, 2015- Serkan Cay
- Ugur Canpolat
- Fatih Ucar
- Ozcan Ozeke
- Firat Ozcan
- Serkan Topaloglu
- and others
Cited in Scopus: 7Inappropriate shock is a frequently seen clinical problem despite advanced technologies used in modern implantable cardioverter-defibrillator (ICD) devices. Our aim was to investigate whether simply raising the ICD detection zones can decrease inappropriate therapies while still providing appropriate therapy. We randomized 223 patients with primary prevention to either the conventional programming group with 3 zones as VT1 (167 to 182 beats/min) with discriminators, VT2 (182 to 200 beats/min) with discriminators, and ventricular fibrillation (>200 beats/min) (n = 100) or the high-zone programming group with 3 zones as VT1 (171 to 200 beats/min) with discriminators, VT2 (200 to 230 beats/min) with discriminators, and ventricular fibrillation (>230 beats/min; n = 101). - Preventive Cardiology
Usefulness of Regional Distribution of Coronary Artery Calcium to Improve the Prediction of All-Cause Mortality
American Journal of CardiologyVol. 115Issue 9p1229–1234Published online: February 11, 2015- Rajesh Tota-Maharaj
- Parag H. Joshi
- Matthew J. Budoff
- Seamus Whelton
- Irfan Zeb
- John Rumberger
- and others
Cited in Scopus: 41Although the traditional Agatston coronary artery calcium (CAC) score is a powerful predictor of mortality, it is unknown if the regional distribution of CAC further improves cardiovascular risk prediction. We retrospectively studied 23,058 patients referred for Agatston CAC scoring, of whom 61% had CAC (n = 14,084). CAC distribution was defined as the number of vessels with CAC (0 to 4, including left main). For multivessel CAC, “diffuse” CAC was defined by decreasing percentage of CAC in the single most affected vessel and by ≤75% total Agatston CAC score in the most calcified vessel. - Preventive CardiologyOpen Access
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
American Journal of CardiologyVol. 115Issue 9p1212–1221Published online: February 11, 2015- Christie M. Ballantyne
- Joel Neutel
- Anne Cropp
- William Duggan
- Ellen Q. Wang
- David Plowchalk
- and others
Cited in Scopus: 144Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol (LDL-C) levels in patients with hypercholesterolemia. In this 24-week, multicenter, double-blind, placebo-controlled, dose-ranging study (NCT01592240), subjects with LDL-C levels ≥80 mg/dl on stable statin therapy were randomized to Q14 days subcutaneous placebo or bococizumab 50, 100, or 150 mg or Q28 days subcutaneous placebo or bococizumab 200 or 300 mg. - Heart Failure
Effect of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Appropriate Implantable Cardiac Defibrillator Shock in Patients With Severe Systolic Heart Failure (from the GRADE Multicenter Study)
American Journal of CardiologyVol. 115Issue 7p924–931Published online: January 16, 2015- Wael A. AlJaroudi
- Marwan M. Refaat
- Robert H. Habib
- Laila Al-Shaar
- Madhurmeet Singh
- Rebecca Gutmann
- and others
Cited in Scopus: 29Sudden cardiac death (SCD) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) decrease cardiac mortality in these cohorts, their role in preventing SCD has not been well established. We sought to determine whether the use of ACEi or ARB in patients with cardiomyopathy is associated with a lower incidence of appropriate implantable cardiac defibrillator (ICD) shocks in the Genetic Risk Assessment of Defibrillator Events study that included subjects with an ejection fraction of ≤30% and ICDs. - Valvular Heart Disease
Meta-Analysis of the Impact of Mitral Regurgitation on Outcomes After Transcatheter Aortic Valve Implantation
American Journal of CardiologyVol. 115Issue 7p942–949Published online: January 16, 2015- Tarun Chakravarty
- Eric Van Belle
- Hasan Jilaihawi
- Amit Noheria
- Luca Testa
- Francesco Bedogni
- and others
Cited in Scopus: 78Significant mitral regurgitation (MR) constitutes an important co-existing valvular heart disease burden in the setting of aortic valve stenosis. There are conflicting reports on the impact of significant MR on outcomes after transcatheter aortic valve implantation (TAVI). We evaluated the impact of MR on outcomes after TAVI by performing a meta-analysis of 8 studies involving 8,927 patients reporting TAVI outcomes based on the presence or absence of moderate-severe MR. Risk ratios (RRs) were calculated using the inverse variance random-effects model. - Miscellaneous
Usefulness of Circulating Amino Acid Profile and Fischer Ratio to Predict Severity of Pulmonary Hypertension
American Journal of CardiologyVol. 115Issue 6p831–836Published online: January 6, 2015- Ryoji Yanagisawa
- Masaharu Kataoka
- Takumi Inami
- Yuichi Momose
- Takashi Kawakami
- Makoto Takei
- and others
Cited in Scopus: 13Plasma amino acid concentrations (aminogram) show distinct patterns under various pathologic conditions. However, the plasma aminogram pattern in patients with pulmonary hypertension (PH) has not been elucidated. We sought to examine whether an aminogram could be predictive of clinical severity in patients with PH. We attained fasting plasma aminograms for 140 patients with PH and then compared the patient plasma amino acid levels with those of age- and gender-matched healthy control subjects. Aminograms revealed that the plasma concentrations of many amino acids were significantly different between patients with PH and healthy control subjects. - Coronary Artery Disease
Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity
American Journal of CardiologyVol. 115Issue 6p716–723Published online: January 5, 2015- Thibault Lhermusier
- Michael J. Lipinski
- Udaya S. Tantry
- Ricardo O. Escarcega
- Nevin Baker
- Kevin P. Bliden
- and others
Cited in Scopus: 28Studies have linked on-treatment platelet reactivity (PR) to adverse clinical outcomes. Because new P2Y12 inhibitors (prasugrel and ticagrelor) have been predominantly tested against clopidogrel, data on pharmacodynamic comparisons between these 2 drugs are scarce. We compared ticagrelor with prasugrel in a network meta-analysis. PubMed, Cochrane, and EMBASE were searched for studies assessing PR in patients with coronary artery disease treated with ticagrelor or prasugrel. All studies using prasugrel and/or ticagrelor providing platelet function measurement data using VerifyNow P2Y12 reaction units (PRUs), platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein phosphorylation, or maximal platelet aggregation (MPA) by light transmission aggregometry were considered eligible. - Coronary Artery Disease
Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography
American Journal of CardiologyVol. 115Issue 6p724–729Published online: January 5, 2015- Hayato Tada
- Masa-aki Kawashiri
- Hirofumi Okada
- Ryota Teramoto
- Tetsuo Konno
- Tsuyoshi Yoshimuta
- and others
Cited in Scopus: 43The aims of this study were (1) to determine whether the accumulation of coronary plaque burden assessed with coronary computed tomography angiography (CCTA) can predict future events and (2) to estimate the onset and progression of coronary atherosclerosis in patients with familial hypercholesterolemia (FH). Consecutive 101 Japanese patients with heterozygous FH (men = 52, mean age 56 ± 16 years, mean low-density lipoprotein cholesterol 264 ± 58 mg/dl) who underwent 64-detector row CCTA without known coronary artery disease were retrospectively evaluated by assigning a score (0 to 5) to each of 17 coronary artery segments according to the Society of Cardiovascular Computed Tomography guidelines. - Arrhythmias and Conduction Disturbances
The AFFORD Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events
American Journal of CardiologyVol. 115Issue 6p763–770Published online: January 5, 2015- Tyler W. Barrett
- Alan B. Storrow
- Cathy A. Jenkins
- Robert L. Abraham
- Dandan Liu
- Karen F. Miller
- and others
Cited in Scopus: 17There is wide variation in the management of patients with atrial fibrillation (AF) in the emergency department (ED). We aimed to derive and internally validate the first prospective, ED-based clinical decision aid to identify patients with AF at low risk for 30-day adverse events. We performed a prospective cohort study at a university-affiliated tertiary-care ED. Patients were enrolled from June 9, 2010, to February 28, 2013, and followed for 30 days. We enrolled a convenience sample of patients in ED presenting with symptomatic AF. - Valvular Heart Disease
Comparison of Balloon-Expandable Versus Self-Expandable Valves for Transcatheter Aortic Valve Implantation in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction
American Journal of CardiologyVol. 115Issue 6p810–815Published online: January 5, 2015- Elisa Covolo
- Francesco Saia
- Massimo Napodano
- Anna Chiara Frigo
- Pierfrancesco Agostoni
- Marco Mojoli
- and others
Cited in Scopus: 2A relevant proportion of patients, classified as severe aortic stenosis on the basis of valve area ≤1 cm2, have a mean transvalvular gradient ≤40 mm Hg, despite a preserved left ventricular ejection fraction (LGSAS). We assessed the clinical and hemodynamic impact of transcatheter aortic valve implantation in patients with symptomatic LGSAS at high risk for surgery or inoperable, according to the type of percutaneous valve implanted. Ninety-five patients received an Edwards SAPIEN valve (Edwards Lifesciences, Irvine, California) and 51 received a Medtronic CoreValve (Medtronic, Inc., Minneapolis, Minnesota). - Coronary Artery Disease
Relationship Between Serum Low-Density Lipoprotein Cholesterol and In-hospital Mortality Following Acute Myocardial Infarction (The Lipid Paradox)
American Journal of CardiologyVol. 115Issue 5p557–562Published online: December 23, 2014- Vanessa S. Reddy
- Quang T. Bui
- Joan R. Jacobs
- Susan M. Begelman
- Dave P. Miller
- William J. French
- and others
Cited in Scopus: 65Lipoprotein levels are currently recognized as independent risk factors for long-term cardiovascular events after acute myocardial infarction (AMI). During the acute-phase reaction after AMI, previous studies have reported trends of decreased low-density lipoprotein cholesterol (LDL-C), increased triglycerides, and variable high-density lipoprotein cholesterol (HDL-C) levels. However, the association between LDL-C and HDL-C levels and in-hospital mortality has not been well established following AMI. - Coronary Artery Disease
Effect of an Invasive Strategy on Outcome in Patients ≥75 Years of Age With Non-ST-Elevation Acute Coronary Syndrome
American Journal of CardiologyVol. 115Issue 5p576–580Published online: December 17, 2014- Gennaro Galasso
- Stefano De Servi
- Stefano Savonitto
- Teresa Strisciuglio
- Raffaele Piccolo
- Nuccia Morici
- and others
Cited in Scopus: 32The Italian Elderly ACS study was the first randomized controlled trial comparing an early aggressive with an initially conservative strategy in patients with non–ST-segment elevation acute coronary syndromes aged ≥75 years, with the results showing no significant benefit of early aggressive therapy. The aim of this study was to evaluate the outcomes of trial patients, according to the treatment actually received during hospitalization. The trial enrolled 313 patients. The primary end point was the composite of death, myocardial infarction (MI), disabling stroke, and repeat hospital stay for cardiovascular causes or bleeding within 1 year. - Coronary Artery Disease
Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial)
American Journal of CardiologyVol. 115Issue 5p563–570Published online: December 17, 2014- Tomotaka Dohi
- Akiko Maehara
- Sorin J. Brener
- Philippe Généreux
- Anthony H. Gershlick
- Roxana Mehran
- and others
Cited in Scopus: 48Infarct size after ST-segment elevation myocardial infarction (STEMI) is associated with long-term clinical outcomes. However, there is insufficient information correlating creatine kinase-MB (CK-MB) or troponin levels to infarct size and infarct location in first-time occurrence of STEMI. We, therefore, assessed the utility of CK-MB measurements after primary percutaneous coronary intervention of a first anterior STEMI using bivalirudin anticoagulation in patients who were randomized to intralesion abciximab versus no abciximab and to manual thrombus aspiration versus no aspiration. - Valvular Heart Disease
Comparison of Outcomes of Patients With Left Ventricular Ejection Fractions ≤30% Versus ≥30% Having Transcatheter Aortic Valve Implantation (from the German Transcatheter Aortic Valve Interventions Registry)
American Journal of CardiologyVol. 115Issue 5p656–663Published online: December 17, 2014- Ulrich Schaefer
- Ralf Zahn
- Mohamed Abdel-Wahab
- Ulrich Gerckens
- Axel Linke
- Steffen Schneider
- and others
Cited in Scopus: 22Transcatheter aortic valve implantation (TAVI) is rapidly evolving in Germany. Especially severe reduced left ventricular ejection fraction (LVEF) is known as a prominent risk factor for adverse outcome in open heart surgery. Thus, the data of the prospective multicenter German Transcatheter Aortic Valve Interventions Registry were analyzed for outcomes in patients with severe depressed LVEF. Data of 1,432 patients were consecutively collected after transcatheter aortic valve implantation. Patients were divided into 2 groups (A: LVEF ≤30%, n = 169, age 79.9 ± 6.7 years, logES 34.2 ± 17.8%; B: LVEF >30%, n = 1,263, age 82.0 ± 6.1 years, logES 18.9 ± 12.0%), and procedural success rates, New York Heart Association classification, and quality of life were compared at 30 days and 1 year, respectively. - Arrhythmias and Conduction Disturbances
Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)
American Journal of CardiologyVol. 115Issue 5p641–646Published online: December 17, 2014- Ashish D. Patel
- Mary K. Tan
- Paul Angaran
- Alan D. Bell
- Murray Berall
- Claudia Bucci
- and others
Cited in Scopus: 19The objectives of this national chart audit (January to June 2013) of 6,346 patients with atrial fibrillation (AF; ≥18 years without a significant heart valve disorder) from 647 primary care physicians were to (1) describe the frequency of stroke and bleed risk assessments in patients with nonvalvular AF by primary care physicians, including the accuracy of these assessments relative to established predictive indexes; (2) outline contemporary methods of anticoagulation used; and (3) report the time in the therapeutic range among patients prescribed warfarin. - Miscellaneous
A Meta-Analysis of Randomized Controlled Trials of the Risk of Bleeding With Apixaban Versus Vitamin K Antagonists
American Journal of CardiologyVol. 115Issue 4p533–541Published online: December 1, 2014- Lahoud Touma
- Kristian B. Filion
- Renée Atallah
- Maria Eberg
- Mark J. Eisenberg
Cited in Scopus: 24Apixaban is one of the new oral anticoagulants, which is prescribed as an alternative to vitamin K antagonists (VKAs). Concerns regarding its bleeding profile persist and require further evaluation. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) to compare the risks of bleeding and all-cause mortality between apixaban and VKAs. The MEDLINE, EMBASE, and Cochrane Library of Clinical Trials databases were systematically searched for RCTs comparing the risks of bleeding and all-cause mortality of apixaban (2.5 or 5 mg twice daily) with those of VKAs. - Valvular Heart Disease
Comparison of Outcomes of Balloon Aortic Valvuloplasty Plus Percutaneous Coronary Intervention Versus Percutaneous Aortic Balloon Valvuloplasty Alone During the Same Hospitalization in the United States
American Journal of CardiologyVol. 115Issue 4p480–486Published online: November 29, 2014- Vikas Singh
- Nileshkumar J. Patel
- Apurva O. Badheka
- Shilpkumar Arora
- Nilay Patel
- Conrad Macon
- and others
Cited in Scopus: 18The use of percutaneous aortic balloon balvotomy (PABV) in high surgical risk patients has resurged because of development of less invasive endovascular therapies. We compared outcomes of concomitant PABV and percutaneous coronary intervention (PCI) with PABV alone during same hospitalization using nation's largest hospitalization database. We identified patients and determined time trends using the International Classification of Diseases, Ninth Revision, Clinical Modification, procedure code for valvulotomy from Nationwide Inpatient Sample database 1998 to 2010. - Valvular Heart Disease
Effect on Outcomes and Exercise Performance of Anemia in Patients With Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement
American Journal of CardiologyVol. 115Issue 4p472–479Published online: November 29, 2014- Hugo DeLarochellière
- Marina Urena
- Ignacio J. Amat-Santos
- Henrique B. Ribeiro
- Ricardo Allende
- Louis Laflamme
- and others
Cited in Scopus: 34The objectives of this study were to determine the causes and impact of anemia and hemoglobin level on functional status, physical performance, and quality of life in the preprocedural evaluation and follow-up of transcatheter aortic valve replacement (TAVR) candidates. A total of 438 patients who underwent TAVR were included. Anemia was defined as a hemoglobin level <12 g/dl in women and <13 g/dl in men. Before TAVR, anemia was encountered in 282 patients (64.4%). A potential treatable cause of anemia was detected in 90.4% of patients and was attributed to iron deficiency in 53% of them. - Coronary Artery Disease
Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)
American Journal of CardiologyVol. 115Issue 4p405–410Published online: November 28, 2014- Ondrej Sochor
- Ryan J. Lennon
- Juan Pablo Rodriguez-Escudero
- John F. Bresnahan
- Ivana Croghan
- Virend K. Somers
- and others
Cited in Scopus: 25Smoke-free ordinance implementation and advances in smoking cessation (SC) treatment have occurred in the past decade; however, little is known about their impact on SC in patients with coronary artery disease. We conducted a retrospective cohort study of 2,306 consecutive patients from Olmsted County, Minnesota, who underwent their first percutaneous coronary intervention (PCI) from 1999 to 2009, and assessed the trends and predictors of SC after PCI. Smoking status was ascertained by structured telephone survey 6 and 12 months after PCI (ending in 2010). - Preventive Cardiology
Usefulness of Measuring Both Body Mass Index and Waist Circumference for the Estimation of Visceral Adiposity and Related Cardiometabolic Risk Profile (from the INSPIRE ME IAA Study)
American Journal of CardiologyVol. 115Issue 3p307–315Published online: November 13, 2014- Julie-Anne Nazare
- Jessica Smith
- Anne-Laure Borel
- Pablo Aschner
- Phil Barter
- Luc Van Gaal
- and others
Cited in Scopus: 108Despite its well-documented relation with visceral adiposity (VAT) and cardiometabolic risk (CMR), whether waist circumference (WC) should be measured in addition to body mass index (BMI) remains debated. This study tested the relevance of adding WC to BMI for the estimation of VAT and CMR. In the International Study of Prediction of Intra-abdominal Adiposity and Its Relationship with Cardiometabolic Risk/Intra-abdominal Adiposity, 297 physicians recruited 4,504 patients (29 countries). Both BMI and WC were measured, whereas VAT and liver fat were assessed by computed tomography. - Arrhythmias and Conduction Disturbances
Meta-Analysis on Risk of Bleeding With Apixaban in Patients With Renal Impairment
American Journal of CardiologyVol. 115Issue 3p323–327Published online: November 13, 2014- Ranjan Pathak
- Anil Pandit
- Paras Karmacharya
- Madan Raj Aryal
- Sushil Ghimire
- Dilli Ram Poudel
- and others
Cited in Scopus: 38Apixaban is a novel oral anticoagulant which is approved for the management of atrial fibrillation and venous thromboembolism prophylaxis. There have been concerns regarding bleeding risks with apixaban in patients with renal impairment. We performed a systematic review and meta-analysis to evaluate the risk of bleeding with apixaban in these patients. Relevant studies were identified through electronic literature searches of MEDLINE, EMBASE, Cochrane library, and clinicaltrials.gov (from inception to February 24, 2014). - Coronary Artery Disease
Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)
American Journal of CardiologyVol. 115Issue 3p288–292Published online: November 13, 2014- Antonio Abbate
- Michael Christopher Kontos
- Nayef Antar Abouzaki
- Ryan David Melchior
- Christopher Thomas
- Benjamin Wallace Van Tassell
- and others
Cited in Scopus: 116Two pilot studies of interleukin-1 (IL-1) blockade in ST-segment elevation myocardial infarction (STEMI) showed blunted acute inflammatory response and overall favorable outcomes at 3 months follow-up. We hereby present a patient-level pooled analysis with extended follow-up of 40 patients with clinically stable STEMI randomized to anakinra, a recombinant IL-1 receptor antagonist, 100 mg/day for 14 days or placebo in a double-blinded fashion. End points included death, cardiac death, recurrent acute myocardial infarction (AMI), stroke, unstable angina, and symptomatic heart failure. - Heart Failure
Relation of Left Ventricular Ejection Fraction and Clinical Features or Co-morbidities to Outcomes Among Patients Hospitalized for Acute Heart Failure Syndromes
American Journal of CardiologyVol. 115Issue 3p334–340Published online: November 11, 2014- Katsuya Kajimoto
- Naoki Sato
- Teruo Takano
- on behalf of the investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry
Cited in Scopus: 18The aim of this study was to evaluate the heterogeneity of the association of a preserved or reduced ejection fraction (EF) with the increased risk of outcomes among patients with acute heart failure syndromes. Of the 4,842 patients enrolled in the Acute Decompensated Heart Failure Syndromes (ATTEND) registry in Japan, 4,720 patients were evaluated to investigate the association of EF and clinical features or co-morbidities with all-cause mortality after admission. The median follow-up period after admission was 519 (388 to 781) days. - Review
Meta-Analysis of the Effects of Lifestyle Modifications on Coronary and Carotid Atherosclerotic Burden
American Journal of CardiologyVol. 115Issue 2p268–275Published online: October 31, 2014- Sunny Jhamnani
- Dhavalkumar Patel
- Layla Heimlich
- Fred King
- Brian Walitt
- Joseph Lindsay
Cited in Scopus: 23Lifestyle modifications are the crux of atherosclerotic disease management. The goal of this study was to determine the effectiveness of diet and exercise in decreasing coronary and carotid atherosclerotic burden. Randomized controlled trials examining the effects of intensive lifestyle measures on atherosclerotic progression in coronary and carotid arteries as measured by baseline and follow-up quantitative coronary angiogram and ultrasonographic carotid intimal-medial thickness (CIMT), respectively, were included. - Preventive Cardiology
Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia
American Journal of CardiologyVol. 115Issue 2p178–182Published online: October 30, 2014- Amit V. Khera
- Arman Qamar
- Muredach P. Reilly
- Richard L. Dunbar
- Daniel J. Rader
Cited in Scopus: 42Recent trials demonstrated substantial improvement in lipid parameters with inhibition of proprotein convertase subtilisin-like/kexin type 9 (PCSK9). Although statins and fibrates have been reported to increase plasma PCSK9 levels, the effect of niacin on PCSK9 is unknown. We investigated the impact of niacin, atorvastatin, and fenofibrate on PCSK9 levels in 3 distinct studies. A statin-only study randomized 74 hypercholesterolemic patients to placebo, atorvastatin 10 mg/day, or atorvastatin 80 mg/day for 16 weeks. - Preventive Cardiology
Cardiovascular and Cerebrovascular Effects in Response to Red Bull Consumption Combined With Mental Stress
American Journal of CardiologyVol. 115Issue 2p183–189Published online: October 29, 2014- Erik Konrad Grasser
- Abdul G. Dulloo
- Jean-Pierre Montani
Cited in Scopus: 30The sale of energy drinks is often accompanied by a comprehensive and intense marketing with claims of benefits during periods of mental stress. As it has been shown that Red Bull negatively impacts human hemodynamics at rest, we investigated the cardiovascular and cerebrovascular consequences when Red Bull is combined with mental stress. In a randomized cross-over study, 20 young healthy humans ingested either 355 ml of a can Red Bull or water and underwent 80 minutes after the respective drink a mental arithmetic test for 5 minutes. - Preventive Cardiology
Frequency of High-Risk Patients Not Receiving High-Potency Statin (from a Large Managed Care Database)
American Journal of CardiologyVol. 115Issue 2p190–195Published online: October 29, 2014- Fatima Rodriguez
- Temitope Olufade
- Kim Heithoff
- Howard S. Friedman
- Prakash Navaratnam
- JoAnne M. Foody
Cited in Scopus: 25We examined trends in low-density lipoprotein cholesterol (LDL-C) goal attainment in high-risk patients and use of high-potency statins (HPS) in a large, managed-care database from 2004 to 2012. The 2013 American Heart Association/American College of Cardiology prevention guidelines recommend that subjects with atherosclerotic cardiovascular disease (ASCVD) should be prescribed HPS therapy, irrespective of LDL-C levels. Previous guidelines recommend an LDL-C target <70 mg/dl. Patients diagnosed with ASCVD based on International Classification of Diseases, Ninth Revision codes with ≥1 LDL-C test from January 2004 to December 2012 were identified in the Optum Insight database. - Heart Failure
Impact of Cardiorespiratory Fitness on the Obesity Paradox in Patients With Systolic Heart Failure
American Journal of CardiologyVol. 115Issue 2p209–213Published online: October 29, 2014- Adrienne L. Clark
- Gregg C. Fonarow
- Tamara B. Horwich
Cited in Scopus: 63Although high body mass index (BMI) is associated with improved outcomes in established heart failure (HF), the impact of cardiorespiratory fitness on this obesity paradox is less clear. We studied 1,675 patients with systolic HF who underwent cardiopulmonary exercise testing at a single university center (77.4% men, mean age 52.2 ± 11.6 years, mean left ventricular ejection fraction 23.2 ± 7.1% and New York Heart Association class III or IV in 79.1%). We evaluated 2-year survival in patients stratified by both BMI (normal 18.5 to 24.9 kg/m2[reference], overweight 25 to 29.9 kg/m2, obese ≥30.0 kg/m2) and by peak oxygen uptake (PKVO2; high >14 ml/kg/minute, low ≤14 ml/kg/minute). - Valvular Heart Disease
Value of the “TAVI2-SCORe” Versus Surgical Risk Scores for Prediction of One Year Mortality in 511 Patients Who Underwent Transcatheter Aortic Valve Implantation
American Journal of CardiologyVol. 115Issue 2p234–242Published online: October 29, 2014- Philippe Debonnaire
- Laura Fusini
- Ron Wolterbeek
- Vasileios Kamperidis
- Philippe van Rosendael
- Frank van der Kley
- and others
Cited in Scopus: 67A bedside-available transcatheter aortic valve implantation (TAVI)–dedicated prognostic risk score is an unmet clinical need. We aimed to develop such a risk score predicting 1-year mortality post-TAVI and to compare it with the performance of the logistic EuroSCORE (LES) I and LES-II and the Society of Thoracic Surgeons' (STS) score. Baseline variables of 511 consecutive patients who underwent TAVI that were independently associated with 1-year mortality post-TAVI were included in the “TAVI2-SCORe.” Discrimination and calibration abilities of the novel score were assessed and compared with surgical risk scores. - Cardiomyopathy
Association of Hemodynamic Profiles With Wait-List Mortality in Children Listed for Heart Transplantation With Idiopathic Dilated Cardiomyopathy
American Journal of CardiologyVol. 115Issue 2p243–248Published online: October 29, 2014- Tajinder P. Singh
- Elizabeth D. Blume
- Peta M. Alexander
- Kimberlee Gauvreau
Cited in Scopus: 3The prognostic significance of intracardiac hemodynamics in children with advanced heart failure is unknown. The purpose of this study was to describe hemodynamic profiles in children with idiopathic dilated cardiomyopathy (IDC) listed for heart transplant (HT) and to assess their association with wait-list mortality. We identified all US children <18 years with IDC listed for HT during 2000 to 2010 with available pulmonary capillary wedge pressure (PCWP) and cardiac index (CIx) data. We excluded children on ventilator or mechanical support at listing. - Valvular Heart Disease
Vascular Complications After Transcatheter Aortic Valve Implantation and Their Association With Mortality Reevaluated by the Valve Academic Research Consortium Definitions
American Journal of CardiologyVol. 115Issue 1p100–106Published online: October 14, 2014- Arie Steinvil
- Eran Leshem-Rubinow
- Amir Halkin
- Yigal Abramowitz
- Eyal Ben-Assa
- Yacov Shacham
- and others
Cited in Scopus: 52Vascular complications (VC) after transcatheter aortic valve implantation (TAVI) are reported using various criteria and several access site approaches. We aimed to describe them in a solely percutaneous transfemoral TAVI approach and their association with survival using both the updated Valve Academic Research Consortium (VARC)-2 criteria and the former VARC-1 criteria. From March 2009 to September 2013, 403 consecutive patients at a mean age (±SD) of 83 ± 6 years underwent percutaneous transfemoral TAVI. - Heart Failure
Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs
American Journal of CardiologyVol. 115Issue 1p75–81Published online: October 14, 2014- Robert J. Mentz
- Xiaojuan Mi
- Puza P. Sharma
- Laura G. Qualls
- Adam D. DeVore
- Katherine Waltman Johnson
- and others
Cited in Scopus: 29Hospitalization for heart failure (HF) is frequently related to dyspnea, yet associations among dyspnea severity, outcomes, and health care costs are unknown. The aim of this study was to describe the characteristics of patients hospitalized for acute HF by dyspnea severity and to examine associations among dyspnea severity, outcomes, and costs. Registry data for patients hospitalized for HF were linked with Medicare claims to evaluate dyspnea and outcomes in patients ≥65 years of age. We classified patients by patient-reported dyspnea severity at admission. - Coronary Artery Disease
Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (from the VCU-Alpha 1-RT Pilot Study)
American Journal of CardiologyVol. 115Issue 1p8–12Published online: October 13, 2014- Antonio Abbate
- Benjamin Wallace Van Tassell
- Sanah Christopher
- Nayef Antar Abouzaki
- Chiara Sonnino
- Claudia Oddi
- and others
Cited in Scopus: 38Alpha-1 antitrypsin (AAT) has broad anti-inflammatory and immunomodulating properties in addition to inhibiting serine proteases. Administration of human plasma–derived AAT is protective in models of acute myocardial infarction in mice. The objective of this study was to determine the safety and tolerability of human plasma–derived AAT and its effects on the acute inflammatory response in non-AAT deficient patients with ST-segment elevation myocardial infarction (STEMI). Ten patients with acute STEMI were enrolled in an open-label, single-arm treatment study of AAT at 60 mg/kg infused intravenously within 12 hours of admission and following standard of care treatment. - Preventive Cardiology
Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease
American Journal of CardiologyVol. 115Issue 1p21–26Published online: October 11, 2014- Salim S. Virani
- LeChauncy D. Woodard
- David J. Ramsey
- Tracy H. Urech
- Julia M. Akeroyd
- Tina Shah
- and others
Cited in Scopus: 110Studies have shown gender disparities in cholesterol care in patients with cardiovascular disease (CVD), with women less likely than men to have low-density lipoprotein cholesterol levels <100 mg/dl. Whether this is related to a lower evidence-based statin or high-intensity statin use is not known. We used a national cohort of 972,532 patients with CVD (coronary heart disease, peripheral artery disease, and ischemic stroke) receiving care in 130 Veterans Health Administration facilities from October 1, 2010, to September 30, 2011, to identify the proportion of male and female patients with CVD receiving any statin and high-intensity statin. - Preventive Cardiology
Heterogeneity in Statin Indications Within the 2013 American College of Cardiology/American Heart Association Guidelines
American Journal of CardiologyVol. 115Issue 1p27–33Published online: October 11, 2014- Ravi V. Shah
- Melvyn Rubenfire
- Robert D. Brook
- João A.C. Lima
- Brahmajee Nallamothu
- Venkatesh L. Murthy
Cited in Scopus: 1A standard (“core”) implementation of American College of Cardiology/American Heart Association 2013 lipid guidelines (based on 10-year risk) dramatically increases the statin-eligible population in older Americans, raising controversy in the cardiovascular community. The guidelines also endorse a more “comprehensive” risk approach based in part on lifetime risk. The impact of this broader approach on statin eligibility remains unclear. We studied the impact of 2 different implementations of the new guidelines (“core” and “comprehensive”) using the National Health and Nutrition Examination Survey. - Arrhythmias and Conduction Disturbances
Comparison of Frequency and Outcome of Major Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation on Versus Not Receiving Warfarin Therapy (from the ATRIA and ATRIA-CVRN Cohorts)
American Journal of CardiologyVol. 115Issue 1p40–46Published online: October 11, 2014- Jeffrey M. Ashburner
- Alan S. Go
- Kristi Reynolds
- Yuchiao Chang
- Margaret C. Fang
- Lisa Fredman
- and others
Cited in Scopus: 12To date, there have been few studies evaluating outcomes of patients with atrial fibrillation (AF) who have experienced gastrointestinal (GI) hemorrhages. We examined short- and long-term mortality of major GI hemorrhage in patients with AF on and off warfarin in recent clinical care. We evaluated this association in the large Anticoagulation and Risk Factors in Atrial fibrillation (ATRIA) and ATRIA-Cardiovascular Research Network (CVRN) California community-based cohorts of patients with AF (study years 1996 to 2003 and 2006 to 2009, respectively), where all events were clinician adjudicated. - Valvular Heart Disease
Prognostic Impact of Pulmonary Artery Systolic Pressure in Patients Undergoing Transcatheter Aortic Valve Replacement for Aortic Stenosis
American Journal of CardiologyVol. 114Issue 10p1562–1567Published online: September 4, 2014- Kalkidan Bishu
- Rakesh M. Suri
- Vuyisile T. Nkomo
- Garvan C. Kane
- Kevin L. Greason
- Guy S. Reeder
- and others
Cited in Scopus: 27Baseline pulmonary hypertension (PH) is a predictor of poor outcomes in patients with severe aortic stenosis (AS). Surgical aortic valve replacement is thought to alleviate PH. The aim of this study was to determine the prognostic impact of PH in patients who underwent transcatheter aortic valve replacement (TAVR). An observational cohort study was conducted using prospectively collected data on 277 consecutive patients with severe AS who underwent TAVR at the Mayo Clinic (Rochester, Minnesota) from November 1, 2008, to June 31, 2013. - Miscellaneous
Reference Values and Calculation of z-Scores of Echocardiographic Measurements of the Normal Pediatric Right Ventricle
American Journal of CardiologyVol. 114Issue 10p1590–1598Published online: September 4, 2014- Martin Koestenberger
- Bert Nagel
- William Ravekes
- Alexander Avian
- Ante Burmas
- Gernot Grangl
- and others
Cited in Scopus: 30Determination of right ventricular (RV) size and function has gained more interest in recent years in adults and children, especially in patients with congenital heart disease. Data on normal RV size parameters in children are scant. The aim of this study was to investigate growth-related changes in RV internal dimensions in a healthy pediatric cohort and the predictive value of RV parameters in identifying enlarged right ventricles in children with secundum-type atrial septal defects (ASD). A prospective study was conducted in a group of 576 healthy children (aged 1 day to 18 years) and 37 children (aged 1.4 to 17.7 years) with moderate-sized to large ASDs. - Coronary Artery Disease
Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study)
American Journal of CardiologyVol. 114Issue 10p1497–1503Published online: August 26, 2014- Jin M. Cheng
- Rohit M. Oemrawsingh
- Hector M. Garcia-Garcia
- K. Martijn Akkerhuis
- Isabella Kardys
- Sanneke P.M. de Boer
- and others
Cited in Scopus: 36The relation between C-reactive protein (CRP) and coronary atherosclerosis is not fully understood. This study aims to investigate the associations among high-sensitivity CRP, coronary plaque burden, and the presence of high-risk coronary lesions as measured by intravascular ultrasound (IVUS) and 1-year cardiovascular outcome. Between 2008 and 2011, grayscale and virtual histology IVUS imaging of a nonculprit coronary artery was performed in 581 patients who underwent coronary angiography for acute coronary syndrome (ACS) or stable angina pectoris. - Heart Failure
Comparative Effectiveness of Cardiac Resynchronization Therapy in Combination With Implantable Defibrillator in Patients With Heart Failure and Wide QRS Duration
American Journal of CardiologyVol. 114Issue 10p1537–1542Published online: August 26, 2014- Kenneth C. Bilchick
- George J. Stukenborg
Cited in Scopus: 1Several clinical trials have established that cardiac resynchronization therapy in combination with an implantable cardioverter-defibrillator improves survival and alleviates heart failure symptoms in appropriately selected patients. Recent guidelines have expanded the indications to include patients with less severe heart failure. The aim of this study was to examine the extent to which cardiac resynchronization therapy in combination with an implantable cardioverter-defibrillator improves survival and reduces risk for heart failure hospitalization in United States Medicare patients who met class I or class IIa recommendations. - Heart Failure
Prognostic Usefulness of Insulin-Like Growth Factor-Binding Protein 7 in Heart Failure With Reduced Ejection Fraction: A Novel Biomarker of Myocardial Diastolic Function?
American Journal of CardiologyVol. 114Issue 10p1543–1549Published online: August 26, 2014- Parul U. Gandhi
- Hanna K. Gaggin
- Alex D. Sheftel
- Arianna M. Belcher
- Rory B. Weiner
- Aaron L. Baggish
- and others
Cited in Scopus: 45Insulin-like growth factor–binding protein 7 (IGFBP7) is a biomarker that has recently been associated with heart failure and cardiac hypertrophy. The aim of this study was to examine IGFBP7 relative to echocardiographic abnormalities reflecting diastolic dysfunction. One hundred twenty-four patients with ambulatory heart failure with reduced ejection fraction and baseline detailed 2-dimensional echocardiograms were followed for a mean of 10 months. IGFBP7 was measured serially at each office visit; 108 patients underwent follow-up echocardiography. - Arrhythmias and Conduction Disturbances
Syncope in Genotype-Negative Long QT Syndrome Family Members
American Journal of CardiologyVol. 114Issue 8p1223–1228Published online: July 30, 2014- Louise R.A. Olde Nordkamp
- Martin H. Ruwald
- Ilan Goldenberg
- Wouter Wieling
- Scott McNitt
- Bronislava Polonsky
- and others
Cited in Scopus: 4Unaffected long-QT syndrome family members (FMs) frequently experience syncope. The aims of this study were to test the hypothesis that syncope events in FMs are benign events and to compare clinical characteristics, triggers eliciting the syncope events, and long-term outcomes between FMs and those with LQT1 or LQT2 mutations from the international Long QT Syndrome Registry. A total of 679 FMs, 864 LQT1 patients, and 782 LQT2 patients were included. Seventy-eight FMs (11%) experienced cardiovascular events. - Arrhythmias and Conduction Disturbances
Effect of Years of Endurance Exercise on Risk of Atrial Fibrillation and Atrial Flutter
American Journal of CardiologyVol. 114Issue 8p1229–1233Published online: July 30, 2014- Marius Myrstad
- Wenche Nystad
- Sidsel Graff-Iversen
- Dag S. Thelle
- Hein Stigum
- Marit Aarønæs
- and others
Cited in Scopus: 69Emerging evidence suggests that endurance exercise increases the risk for atrial fibrillation (AF) in men, but few studies have investigated the dose-response relation between exercise and risk for atrial arrhythmias. Both exposure to exercise and reference points vary among studies, and previous studies have not differentiated between AF and atrial flutter. The aim of this study was to assess the risk for atrial arrhythmias by cumulative years of regular endurance exercise in men. To cover the range from physical inactivity to long-term endurance exercise, the study sample in this retrospective cohort study was based on 2 distinct cohorts: male participants in a long-distance cross-country ski race and men from the general population, in total 3,545 men aged ≥53 years. - Heart Failure
Free Light Chains in Patients With Acute Heart Failure Secondary to Atherosclerotic Coronary Artery Disease
American Journal of CardiologyVol. 114Issue 8p1243–1248Published online: July 30, 2014- Eduard Shantsila
- Benjamin Wrigley
- Gregory Yoke Hong Lip
Cited in Scopus: 9Increased combined free light chains (cFLCs) are strongly prognostic of death in general populations and in patients with chronic kidney disease, but scarce data are available on cFLC in heart failure (HF). The aim of this study was to assess the dynamics and prognostic significance of cFLC levels in patients after admission with acute HF (AHF). cFLC measurements were compared in 49 patients with AHF, 37 patients with stable HF, 43 patients with stable coronary artery disease and without HF (“disease controls”), and 37 healthy controls. - Coronary Artery Disease
Effects of Baseline Coronary Occlusion and Diabetes Mellitus in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
American Journal of CardiologyVol. 114Issue 8p1145–1150Published online: July 29, 2014- Raffaele Piccolo
- Gennaro Galasso
- Allan Zeeberg Iversen
- Ingo Eitel
- Alberto Dominguez-Rodriguez
- Youlan L. Gu
- and others
Cited in Scopus: 11Several studies have highlighted the prognostic role of preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow in the infarct-related artery (IRA) in patients with ST-segment elevation myocardial infarction (STEMI). However, the impact of preprocedural IRA occlusion in patients with diabetes with STEMI has been insufficiently studied. The aim of this study was to evaluate the effects of baseline IRA occlusion and diabetic status in patients with STEMI who underwent primary percutaneous coronary intervention by using data from a pooled analysis of randomized trials comparing intracoronary with intravenous abciximab bolus administration. - Coronary Artery Disease
Effect of Radial-to-Femoral Access Crossover on Adverse Outcomes in Primary Percutaneous Coronary Intervention
American Journal of CardiologyVol. 114Issue 8p1165–1173Published online: July 29, 2014- Lorenzo Azzalini
- Razi Khan
- Malek Al-Hawwas
- Raja Hatem
- Annik Fortier
- Philippe L. L’Allier
- and others
Cited in Scopus: 14We aimed to describe the impact of the vascular access used when patients are treated with primary percutaneous coronary intervention (PPCI) and to assess whether this translates into differences in angiographic outcomes. Patients with ST-elevation myocardial infarction who underwent PPCI were divided into 3 groups: successful radial access (RA), successful femoral access (FA), and Crossover (failed RA with need for bailout FA) groups. Vascular access–related time (VART) was defined as the delay in PPCI that can be attributed to vascular access–related issues. - Coronary Artery Disease
Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study)
American Journal of CardiologyVol. 114Issue 8p1192–1197Published online: July 29, 2014- Jennifer L. Jarvie
- Mary A. Whooley
- Mathilda C. Regan
- Nancy L. Sin
- Beth E. Cohen
Cited in Scopus: 23Higher levels of physical activity are associated with lower rates of coronary heart disease (CHD). Previous studies have suggested that this is due partly to lower levels of inflammation and insulin resistance. The aim of this study was to determine whether physical activity level was associated with inflammation or insulin resistance during a 5-year period in outpatients with known CHD. A total of 656 participants from the Heart and Soul Study, a prospective cohort study of outpatients with documented CHD, were evaluated. - Coronary Artery Disease
Effect of Preinfarction Angina Pectoris on Long-term Survival in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention
American Journal of CardiologyVol. 114Issue 8p1179–1186Published online: July 29, 2014- Tomohiko Taniguchi
- Hiroki Shiomi
- Toshiaki Toyota
- Takeshi Morimoto
- Masaharu Akao
- Kenji Nakatsuma
- and others
Cited in Scopus: 13The influence of preinfarction angina pectoris (AP) on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) remains controversial. In 5,429 patients with acute myocardial infarction (AMI) enrolled in the Coronary Revascularization Demonstrating Outcome Study in Kyoto AMI Registry, the present study population consisted of 3,476 patients with STEMI who underwent primary PCI within 24 hours of symptom onset and in whom the data on preinfarction AP were available. - Peripheral Arterial Disease
Meta-Analysis of Revascularization Versus Medical Therapy for Atherosclerotic Renal Artery Stenosis
American Journal of CardiologyVol. 114Issue 7p1116–1123Published online: July 17, 2014- Irbaz B. Riaz
- Muhammad Husnain
- Haris Riaz
- Majid Asawaeer
- Jawad Bilal
- Anil Pandit
- and others
Cited in Scopus: 47The aim of the study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal artery stenosis (ARAS). ARAS is the most common cause of secondary hypertension and is associated with several complications, such as renal failure, coronary artery disease, cardiac destabilization, and stroke. Medical therapy is the cornerstone for management of ARAS; however, numerous trials have compared medical therapy with revascularization in the form of percutaneous renal artery angioplasty (PTRA) or percutaneous renal artery angioplasty with stent placement (PTRAS). - Arrhythmias and Conduction Disturbances
Meta-Analysis of Left Ventricular Hypertrophy and Sustained Arrhythmias
American Journal of CardiologyVol. 114Issue 7p1049–1052Published online: July 17, 2014- Saurav Chatterjee
- Chirag Bavishi
- Partha Sardar
- Vikram Agarwal
- Parasuram Krishnamoorthy
- Tomasz Grodzicki
- and others
Cited in Scopus: 81Presence of left ventricular hypertrophy (LVH) has been reported to be associated with supraventricular and ventricular arrhythmias, but the association has not been systematically quantified and evaluated. A systematic search of studies in MEDLINE, EMBASE, CINAHL, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials databases was undertaken through April 2014. Studies reporting on LVH and sustained arrhythmias such as atrial fibrillation and supraventricular tachycardias (SVTs) and ventricular arrhythmias (tachycardia and fibrillation) were identified. - Peripheral Arterial Disease
Effectiveness of Screening for Abdominal Aortic Aneurysm During Echocardiography
American Journal of CardiologyVol. 114Issue 7p1100–1104Published online: July 17, 2014- Victor Aboyans
- Vincent Bataille
- Pascale Bliscaux
- Stéphane Ederhy
- Didier Filliol
- Benjamin Honton
- and others
Cited in Scopus: 30Screening patients with abdominal aortic aneurysm (AAA) is associated with reduced AAA-related mortality, but population screening is poorly implemented. Opportunistic screening during imaging for other indications might be efficient. Single-center series reported AAA rates of 0.8% to 6.5% in patients undergoing transthoracic echocardiography (TTE), with disparities due to selection bias. In this first multicenter study, we aimed to assess the feasibility and criteria for screening AAA during TTE in real-life practice. - Cardiomyopathy
Characteristics of Trabeculated Myocardium Burden in Young and Apparently Healthy Adults
American Journal of CardiologyVol. 114Issue 7p1094–1099Published online: July 17, 2014- Helena Tizón-Marcos
- Maria de la Paz Ricapito
- Philippe Pibarot
- Olivier Bertrand
- Karine Bibeau
- Florent Le Ven
- and others
Cited in Scopus: 18Increased myocardial trabeculations define noncompaction cardiomyopathy (NCC). Imaging advancements have led to increasingly common identification of prominent trabeculations with unknown implications. We quantified and determined the impact of trabeculations' burden on cardiac function and stretch in a population of healthy young adults. One hundred adults aged 18 to 35 years (28 ± 4 years, 55% women) without known cardiovascular disease were prospectively studied by cardiovascular magnetic resonance. - Coronary Artery Disease
Comparison of Five-Year Outcomes of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fractions ≤50% Versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2)
American Journal of CardiologyVol. 114Issue 7p988–996Published online: July 16, 2014- Akira Marui
- Takeshi Kimura
- Noboru Nishiwaki
- Kazuaki Mitsudo
- Tatsuhiko Komiya
- Michiya Hanyu
- and others
Cited in Scopus: 45Coronary heart disease is a major risk factor for left ventricular (LV) systolic dysfunction. However, limited data are available regarding long-term benefits of percutaneous coronary intervention (PCI) in the era of drug-eluting stent or coronary artery bypass grafting (CABG) in patients with LV systolic dysfunction with severe coronary artery disease. We identified 3,584 patients with 3-vessel and/or left main disease of 15,939 patients undergoing first myocardial revascularization enrolled in the CREDO-Kyoto PCI/CABG Registry Cohort-2. - Miscellaneous
Reference Values for Echocardiographic Assessment of the Diameter of the Aortic Root and Ascending Aorta Spanning All Age Categories
American Journal of CardiologyVol. 114Issue 6p914–920Published online: July 3, 2014- Laurence Campens
- Laurent Demulier
- Katya De Groote
- Kristof Vandekerckhove
- Daniël De Wolf
- Mary J. Roman
- and others
Cited in Scopus: 126Thoracic aortic dilatation requires accurate and timely detection to prevent progression to thoracic aortic aneurysm and aortic dissection. The detection of thoracic aortic dilatation necessitates the availability of cut-off values for normal aortic diameters. Tools to evaluate aortic dimension above the root are scarce and inconsistent regarding age groups. The aim of this study was to provide reference values for aortic root and ascending aortic diameters on the basis of transthoracic echocardiographic measurements in a large cohort of children and adults. - Miscellaneous
Impact of Symptoms, Gender, Co-Morbidities, and Operator Volume on Outcome of Carotid Artery Stenting (from the Nationwide Inpatient Sample [2006 to 2010])
American Journal of CardiologyVol. 114Issue 6p933–941Published online: July 3, 2014- Apurva O. Badheka
- Ankit Chothani
- Sidakpal S. Panaich
- Kathan Mehta
- Nileshkumar J. Patel
- Abhishek Deshmukh
- and others
Cited in Scopus: 25The increase in the number of carotid artery stenting (CAS) procedures over the last decade has necessitated critical appraisal of procedural outcomes and patterns of utilization including cost analysis. The main objectives of our study were to evaluate the postprocedural mortality and complications after CAS and the patterns of resource utilization in terms of length of stay (LOS) and cost of hospitalization. We queried the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample from 2006 to 2010 using the International Classification of Diseases, Ninth Revision, procedure code of 00.63 for CAS. - Valvular Heart Disease
Transient, Subclinical Atrial Fibrillation and Risk of Systemic Embolism in Patients With Rheumatic Mitral Stenosis in Sinus Rhythm
American Journal of CardiologyVol. 114Issue 6p869–874Published online: July 2, 2014- Ganesan Karthikeyan
- Ramamoorthy Ananthakrishnan
- Niveditha Devasenapathy
- Rajiv Narang
- Rakesh Yadav
- Sandeep Seth
- and others
Cited in Scopus: 22Stroke and systemic embolism occur frequently in patients with rheumatic mitral stenosis (MS) in sinus rhythm (SR), but the risk and predictors of embolic events in this population are not well studied. The aim of this study was to determine if transient, subclinical atrial fibrillation (AF) increases the risk of systemic embolism in patients with MS in SR. A single-center, prospective observational study of patients with rheumatic MS in SR was performed. The rate of the composite primary outcome of stroke, transient ischemic attack, or non–central nervous system embolism was determined, as well as the predictive value of Holter-detected episodes of transient (<30 seconds), subclinical AF for this outcome. - Systemic Hypertension
Meta-Analysis of the Effect of Renal Denervation on Blood Pressure and Pulse Pressure in Patients With Resistant Systemic Hypertension
American Journal of CardiologyVol. 114Issue 6p856–861Published online: July 2, 2014- Samir B. Pancholy
- Ghanshyam Palamaner Subash Shantha
- Tejas M. Patel
- Paul A. Sobotka
- David E. Kandzari
Cited in Scopus: 20Data comparing the effect of renal denervation (RD) with those of maximal medical therapy (MMT) have shown conflicting results. Also, effect of RD on pulse pressure (PP) has not been evaluated. The aim of this meta-analysis was to compare the effect of RD with that of MMT on blood pressure (BP) and PP at 6-month follow-up in patients with resistant hypertension. Randomized controlled trials and nonrandomized controlled trials reporting systolic BP, diastolic BP, and PP results in RD and MMT groups at 6-month follow-up in patients with resistant hypertension were systematically reviewed, and eligible citations were pooled using a random-effects model. - Valvular Heart Disease
Meta-Analysis of Mortality Outcomes and Mitral Regurgitation Evolution in 4,839 Patients Having Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis
American Journal of CardiologyVol. 114Issue 6p875–882Published online: July 2, 2014- Anna Sannino
- Maria Angela Losi
- Gabriele Giacomo Schiattarella
- Giuseppe Gargiulo
- Cinzia Perrino
- Eugenio Stabile
- and others
Cited in Scopus: 49Transcatheter aortic valve implantation (TAVI) is an effective alternative therapy in selected patients with severe aortic stenosis. The role and effects of coexistent moderate to severe mitral regurgitation (msMR) in patients who undergo TAVI remain unclear. Thirteen studies enrolling 4,839 patients who underwent TAVI, including patients with msMR, were considered in a meta-analysis and analyzed for all-cause-mortality; a further meta-analysis was performed to assess mitral regurgitation (MR) evolution after TAVI. - Miscellaneous
Family History as a Risk Factor for Peripheral Arterial Disease
American Journal of CardiologyVol. 114Issue 6p928–932Published online: July 2, 2014- Mahyar Khaleghi
- Iyad N. Isseh
- Kent R. Bailey
- Iftikhar J. Kullo
Cited in Scopus: 20The association of a family history of peripheral arterial disease (PAD) with the presence of PAD is largely unknown. We conducted a case-control study of 2,296 patients with PAD (69 ± 10 years, 64% men) and 4,390 controls (66 ± 11 years, 62% men) identified from noninvasive vascular and stress testing laboratories at Mayo Clinic, Rochester, Minnesota, from October 2006 through June 2012. PAD was defined as an ankle brachial index of ≤0.9 at rest and/or after exercise, a history of lower extremity revascularization, or having poorly compressible leg arteries. - Coronary Artery Disease
Ability of Low Antihypertensive Medication Adherence to Predict Statin Discontinuation and Low Statin Adherence in Patients Initiating Treatment After a Coronary Event
American Journal of CardiologyVol. 114Issue 6p826–831Published online: July 1, 2014- Paul Muntner
- Huifeng Yun
- Pradeep Sharma
- Elizabeth Delzell
- Shia T. Kent
- Meredith L. Kilgore
- and others
Cited in Scopus: 26Low statin adherence and discontinuation of statins are common in patients with coronary heart disease. We hypothesized that low antihypertensive medication adherence would be associated with future statin discontinuation and low adherence in patients initiating statins. Using a 5% national sample of Medicare beneficiaries, we conducted a cohort study of Medicare beneficiaries initiating statins after hospitalization for acute myocardial infarction or coronary revascularization in 2007, 2008, and 2009. - Arrhythmias and Conduction Disturbances
A Genome-Wide Association Study to Identify Genomic Modulators of Rate Control Therapy in Patients With Atrial Fibrillation
American Journal of CardiologyVol. 114Issue 4p593–600Published online: June 7, 2014- Matthew J. Kolek
- Todd L. Edwards
- Raafia Muhammad
- Adnan Balouch
- M. Benjamin Shoemaker
- Marcia A. Blair
- and others
Cited in Scopus: 10For many patients with atrial fibrillation, ventricular rate control with atrioventricular (AV) nodal blockers is considered first-line therapy, although response to treatment is highly variable. Using an extreme phenotype of failure of rate control necessitating AV nodal ablation and pacemaker implantation, we conducted a genome-wide association study (GWAS) to identify genomic modulators of rate control therapy. Cases included 95 patients who failed rate control therapy. Controls (n = 190) achieved adequate rate control therapy with ≤2 AV nodal blockers using a conventional clinical definition. - Arrhythmias and Conduction Disturbances
Relation of Systolic, Diastolic, and Pulse Pressures and Aortic Distensibility With Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis)
American Journal of CardiologyVol. 114Issue 4p587–592Published online: June 7, 2014- Nicholas S. Roetker
- Lin Y. Chen
- Susan R. Heckbert
- Saman Nazarian
- Elsayed Z. Soliman
- David A. Bluemke
- and others
Cited in Scopus: 33Previous research suggests that elevated pulse pressure (PP) is a risk factor for atrial fibrillation (AF) independently of mean arterial pressure (MAP). PP may serve as an indirect measure of aortic stiffness (reduced distensibility), but whether directly measured aortic distensibility is related to risk for AF has not yet been studied. This analysis included 6,630 participants aged 45 to 84 years from the Multi-Ethnic Study of Atherosclerosis. At baseline, blood pressure and other relevant covariates were measured using standardized protocols. - Miscellaneous
Impact of Obstructive Sleep Apnea on Abdominal Aortic Diameters
American Journal of CardiologyVol. 114Issue 4p618–623Published online: June 7, 2014- Ryo Tachikawa
- Satoshi Hamada
- Masanori Azuma
- Yoshiro Toyama
- Kimihiko Murase
- Kiminobu Tanizawa
- and others
Cited in Scopus: 14Although obesity has been reported to be a potential risk factor for abdominal aortic dilatation, the impact of obstructive sleep apnea (OSA) on the abdominal aortic diameter remains unknown. We retrospectively reviewed 427 patients aged >45 years who underwent polysomnography and abdominal computed tomography from November 2008 to February 2012. Aortic diameters were measured at 3 locations: upper, infrarenal, and lower abdominal aorta. OSA was defined as non-OSA (apnea-hypopnea index [AHI] <10, n = 58), mild to moderate (AHI 10 to 30, n = 167), and severe (AHI ≥30, n = 202). - Miscellaneous
Attitudes of Early-Career Cardiologists in Japan About Their Cardiovascular Training Programs
American Journal of CardiologyVol. 114Issue 4p629–634Published online: June 7, 2014- Takashi Kohno
- Shun Kohsaka
- Kazuki Ohshima
- Yasuyoshi Takei
- Akira Yamashina
- Keiichi Fukuda
Cited in Scopus: 2Understanding the perspective of early-career cardiologists is important to design effective responses to the challenges in modern cardiovascular (CV) training programs. We conducted a web-based survey on a total of 272 early-career cardiologists (within 10 postgraduate years) who registered for the 2011 annual Japanese Circulation Society Meeting. Main outcome measures were satisfaction with their training, confidence in their clinical skills, and professional expectations, scaled from 0 to 10. - Miscellaneous
Muscle Mass, Visceral Fat, and Plasma Levels of B-Type Natriuretic Peptide in Healthy Individuals (from the J-SHIPP Study)
American Journal of CardiologyVol. 114Issue 4p635–640Published online: June 7, 2014- Taiji Yamashita
- Katsuhiko Kohara
- Yasuharu Tabara
- Masayuki Ochi
- Tokihisa Nagai
- Yoko Okada
- and others
Cited in Scopus: 12A paradoxical negative association between obesity and the plasma B-type natriuretic peptide (BNP) level has been firmly established. An individual's fat mass increases and muscle mass decreases with aging. Because aging is a potent determinant of plasma BNP levels, BNP may be related not only to fat mass but also to muscle mass. However, no studies have evaluated the associations between body composition and plasma levels of BNP. We performed a cross-sectional study to investigate these associations in 1,431 apparently healthy middle-aged to elderly subjects. - Coronary Artery Disease
Usefulness of Postmarket Studies to Evaluate Long-Term Safety of Coronary Eluting Stents (from the ENDEAVOR and PROTECT Programs)
American Journal of CardiologyVol. 114Issue 4p528–533Published online: June 5, 2014- Moshe Vardi
- Jeremiah Perez
- Paula J. Griffin
- David A. Burke
- Robert W. Yeh
- Donald E. Cutlip
Cited in Scopus: 4Differences in enrollment criteria and protocol requirements are believed to affect patient representation and outcomes from premarket and postmarket surveillance (PMS) trials. These differences have not been assessed in studies evaluating coronary stenting. We aimed to assess differences in clinical profile and long-term outcomes in patients enrolled into premarket versus PMS trials assessing the Endeavor zotarolimus-eluting stent (E-ZES). We pooled patient-level data for 2,132 and 4,357 E-ZES–treated subjects enrolled into the ENDEAVOR program (premarket) and Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PMS), respectively. - Coronary Artery Disease
Comparison of Long-Term Mortality After Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention in Patients Living Alone Versus Not Living Alone at the Time of Hospitalization
American Journal of CardiologyVol. 114Issue 4p522–527Published online: June 5, 2014- Kenji Nakatsuma
- Hiroki Shiomi
- Hiroki Watanabe
- Takeshi Morimoto
- Tomohiko Taniguchi
- Toshiaki Toyota
- and others
Cited in Scopus: 8Living alone was reported to be associated with increased risk of cardiovascular disease. There are, however, limited data on the relation between living alone and all-cause mortality in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). The Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) AMI registry was a cohort study of patients with AMI enrolled in 26 hospitals in Japan from 2005 through 2007. For the current analysis, we included those patients who underwent PCI within 24 hours of symptom onset, and we assessed their living status to determine if living alone would be an independent prognostic risk factor. - Coronary Artery Disease
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With End-Stage Renal Disease Requiring Dialysis (5-Year Outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2)
American Journal of CardiologyVol. 114Issue 4p555–561Published online: June 5, 2014- Akira Marui
- Takeshi Kimura
- Noboru Nishiwaki
- Kazuaki Mitsudo
- Tatsuhiko Komiya
- Michiya Hanyu
- and others
Cited in Scopus: 45Ischemic heart disease is a major risk factor for morbidity and mortality in patients with end-stage renal disease. However, long-term benefits of percutaneous coronary intervention (PCI) relative to coronary artery bypass grafting (CABG) in those patients is still unclear in the drug-eluting stent era. We identified 388 patients with multivessel and/or left main disease with end-stage renal disease requiring dialysis among 15,939 patients undergoing first coronary revascularization enrolled in the Coronary REvascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2 (PCI: 258 patients and CABG: 130 patients). - Arrhythmias and Conduction Disturbances
Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation
American Journal of CardiologyVol. 114Issue 4p577–582Published online: June 5, 2014- Madan Raj Aryal
- Anene Ukaigwe
- Anil Pandit
- Paras Karmacharya
- Rajesh Pradhan
- Naba Raj Mainali
- and others
Cited in Scopus: 43Several studies have been conducted to study the efficacy and safety of rivaroxaban in the atrial fibrillation periprocedural ablation period with similar rates of thromboembolism and major bleeding risks compared with warfarin or dabigatran. We sought to systematically review this evidence using pooled data from multiple studies. Studies comparing rivaroxaban with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation were identified through electronic literature searches of MEDLINE, EMBASE, clinicaltrials.gov, and the Cochrane library up to March 2014. - Preventive Cardiology
Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials
American Journal of CardiologyVol. 113Issue 12p2018–2020Published online: April 4, 2014- Sripal Bangalore
- Rana Fayyad
- G. Kees Hovingh
- Rachel Laskey
- Liffert Vogt
- David A. DeMicco
- and others
Cited in Scopus: 35A recent study has shown an association between high-potency statins and risk of acute kidney injury. However, these data are from observational studies, and it is not clear if similar signal is seen from randomized controlled trials. We evaluated the risk of renal-associated serious adverse events (SAEs) using statins versus placebo trials and the high-dose versus low-dose statin trials that were available to us. The outcome of interest was renal-related SAEs. The incidence of adverse events relating to kidney injury was determined through review of the adverse event database. - Coronary Artery Disease
Analysis of the Invasive Strategy Decision in Patients With Acute Coronary Syndrome Without ST-Segment Elevation in a Real-World Setting
American Journal of CardiologyVol. 113Issue 12p1956–1961Published online: April 3, 2014- Maximiliano De Abreu
- Javier A. Mariani
- Alejandro Silberstein
- Cristian Guridi
- Gabriela Hecht
- Juan A. Gagliardi
- and others
Cited in Scopus: 1Observational studies have reported a marked discrepancy between the risk estimated by scores and the use of an invasive strategy in patients with acute coronary syndromes. The objective is to describe the criteria used to decide an early invasive strategy and to determine the differences between those criteria and the thrombolysis in myocardial infarction risk score (TRS). Patients entered to the Epi-Cardio registry with a diagnosis of non–ST-elevation acute coronary syndrome were analyzed. A logistic regression model including variables associated with an early invasive strategy was developed and validated in 2 consecutive cohorts. - Coronary Artery Disease
Impact of Cardiac Rehabilitation on Angiographic Outcomes After Drug-Eluting Stents in Patients With De Novo Long Coronary Artery Lesions
American Journal of CardiologyVol. 113Issue 12p1977–1985Published online: April 3, 2014- Jong-Young Lee
- Sung-Cheol Yun
- Jung-Min Ahn
- Duk-Woo Park
- Soo-Jin Kang
- Seung-Whan Lee
- and others
Cited in Scopus: 6Cardiac rehabilitation (CR) can reduce cardiovascular mortality and morbidity in coronary artery disease. Long coronary artery lesions may be associated with adverse outcomes after drug-eluting stent (DES) implantation. The purpose of this study was to evaluate angiographic outcomes after a comprehensive CR program in patients with DESs for long coronary artery lesions. A total of 576 patients treated with DESs for long (≥25 mm) coronary lesions were enrolled in this prospective CR registry. Comprehensive CR programs were successfully performed in 288 patients (50%). - Valvular Heart Disease
A Simple Risk Tool (the OBSERVANT Score) for Prediction of 30-Day Mortality After Transcatheter Aortic Valve Replacement
American Journal of CardiologyVol. 113Issue 11p1851–1858Published online: March 19, 2014- Davide Capodanno
- Marco Barbanti
- Corrado Tamburino
- Paola D'Errigo
- Marco Ranucci
- Gennaro Santoro
- and others
Cited in Scopus: 110Risk stratification tools used in patients with severe aortic stenosis have been mostly derived from surgical series. Although specific predictors of early mortality with transcatheter aortic valve replacement (TAVR) have been identified, the prognostic impact of their combination is unexplored. We sought to develop a simple score, using preprocedural variables, for prediction of 30-day mortality after TAVR. A total of 1,878 patients from a national multicenter registry who underwent TAVR were randomly assigned in a 2:1 manner to development and validation data sets. - Arrhythmias and Conduction Disturbances
Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
American Journal of CardiologyVol. 113Issue 11p1815–1821Published online: March 17, 2014- Abhishek Sharma
- Andrew J. Einstein
- Ajay Vallakati
- Armin Arbab-Zadeh
- Marcella Donovan Walker
- Debabrata Mukherjee
- and others
Cited in Scopus: 40Clinical studies suggest an association between bisphosphonate use and new-onset atrial fibrillation (AF). Intravenous bisphosphonates more potently increase the release of inflammatory cytokines than do oral bisphosphonates; thus, the risk of developing AF may be greater with intravenous preparations. We have evaluated incidence of new-onset AF with use of oral and intravenous bisphosphonates through a systematic review and meta-analysis of the literature. We searched PubMed, CINAHL, Cochrane Central Register of Controlled Trials, Scopus, and EMBASE databases for observational studies and randomized controlled trials (RCTs) published from 1966 to April 2013 that reported the number of patients developing AF with use of oral or intravenous bisphosphonates.